NEUCLONE
NeuClone is a biotechnology company developing and commercializing high quality biosimilars.
NEUCLONE
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2007-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.neuclone.com
Status:
Active
Contact:
+61292094020
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
G2 Therapies
G2 is a privately funded biotechnology company that develops and commercializes novel antibody-based therapies in inflammation and cancer.
Molecular Probes
Molecular Probes was a biotechnology company located in Eugene, Oregon specializing in fluorescence.
NanoLight Technologies
NanoLight Technologies is a biotechnology company developing broad applications of natural and light-emitting marine proteins.
Surrogen
Surrogen is a biotech company delivering better models to understand human disease.
Current Employees Featured
Official Site Inspections
http://www.neuclone.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: 182.54.224.111
- IP address: 182.54.224.111
- Location: Rosebery Australia
- Latitude: -33.9186
- Longitude: 151.2046
- Timezone: Australia/Sydney
- Postal: 2018
More informations about "NeuClone"
NeuClone | Increasing Patient Access
Developing a diverse portfolio of clinically identical biosimilars for patients, globally. We value affordable access to healthcare, the quality and integrity of our science, and a strong patient …See details»
Who We Are - NeuClone
NeuClone is a clinical-stage biopharmaceutical company with an exclusive focus on the development and commercialisation of high quality biosimilar products. Led by a team of …See details»
Our People - NeuClone
Since NeuClone’s establishment in 2007, Dr. Sunstrom has held the title of CEO. With over twenty years’ experience in the biopharmaceutical industry, including more than ten years’ …See details»
NeuClone - Crunchbase Company Profile & Funding
NeuClone is a biotechnology company developing and commercializing high quality biosimilars.See details»
NeuClone Company Profile - Office Locations, Competitors ... - Craft
NeuClone is a clinical-stage biopharmaceutical company that develops and commercializes biosimilar products. It uses the NeuMAX integrated CHO cell-based platform for the …See details»
NeuClone Company Profile 2024: Valuation, Funding & Investors
Developer of biosimilar monoclonal antibody drugs designed for the treatment of diseases such as cancer and autoimmune disorders. The company provides complex biologics, monoclonal …See details»
NeuClone - LinkedIn
NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating...See details»
NeuClone: Contact Details and Business Profile - RocketReach
NeuClone is a Pharmaceutical Manufacturing, Business Services General, and Biotechnology company_reader located in Sydney, New South Wales with $6 million in revenue and 15 …See details»
NeuClone - Products, Competitors, Financials, Employees, …
NeuClone is a clinical-stage biopharmaceutical company focused on the development and commercialization of biosimilar products. Use the CB Insights Platform to explore NeuClone's …See details»
A Profile of a Lesser Known BIosimilar Player: NeuClone | BR&R
Sep 10, 2020 · NeuClone has been operating since 2007, with its founding CEO, Noelle Sundstrom, at the helm. The company has historically focused on clinical trial development of …See details»
NeuClone - Overview, News & Similar companies | ZoomInfo.com
Aug 31, 2020 · NeuClone contact info: Phone number: +61 292094020 Website: www.neuclone.com What does NeuClone do? NeuClone is a clinical-stage biopharmaceutical …See details»
NeuClone | Scientist.com
NeuClone generates robust industrial cell lines to support protein expression and manufacture of biological active pharmaceutical ingredients. If your organization has a Scientist.com …See details»
NeuClone | About Us
It has come to our attention that scammers are targeting unsuspecting individuals, falsely claiming to represent our esteemed organisation, NeuClone Pty Ltd. They may contact you through …See details»
NeuClone Company Profile
Clinical-stage biopharmaceutical company focused on high quality, affordable biosimilars. NeuClone’s ‘Right from the Start®’ development approach enables efficient production of high …See details»
NeuClone Announces First Human Dose of Stelara - Business Wire
Oct 17, 2019 · SYDNEY-- ( BUSINESS WIRE )-- NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced …See details»
Neuclone - VentureRadar
NeuClone is a clinical-stage biopharmaceutical company, with an exclusive focus on the development and commercialisation of high quality biosimilar... ... Find out more about …See details»
NeuClone Developing Biosimilars of PD-1 Inhibitors - Center for …
Sep 1, 2020 · Sydney, Australia-based NeuClone Pharmaceuticals disclosed that it is actively developing 2 biosimilars that will reference 2 blockbuster programmed death-1 (PD-1) immune …See details»
NeuClone | News
NeuClone’s trial is being prosecuted in Australia by a Top 5 global Clinical Research Organization (CRO) with data output expected to be submitted to global regulatory agencies such as the …See details»
Working at NeuClone - Glassdoor
Glassdoor gives you an inside look at what it's like to work at NeuClone, including salaries, reviews, office photos, and more. This is the NeuClone company profile. All content is posted …See details»
Pipeline - NeuClone
NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. The development stage of NeuClone’s eight publicly disclosed biosimilar products …See details»